Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Inhibrx Biosciences (INBX) Income from Continuing Operations (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Income from Continuing Operations for 3 consecutive years, with 35256000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 19.62% to 35256000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 155086000.0, a 109.44% decrease, with the full-year FY2024 number at 1687572000.0, up 803.96% from a year prior.
  • Income from Continuing Operations was 35256000.0 for Q3 2025 at Inhibrx Biosciences, down from 28654000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 1858011000.0 in Q2 2024 to a low of 91970000.0 in Q4 2023.
  • A 3-year average of 139766700.0 and a median of 43587500.0 in 2024 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: skyrocketed 4873.31% in 2024, then crashed 101.54% in 2025.
  • Inhibrx Biosciences' Income from Continuing Operations stood at 91970000.0 in 2023, then soared by 47.96% to 47865000.0 in 2024, then increased by 26.34% to 35256000.0 in 2025.
  • Per Business Quant, the three most recent readings for INBX's Income from Continuing Operations are 35256000.0 (Q3 2025), 28654000.0 (Q2 2025), and 43311000.0 (Q1 2025).